Endo Health Solutions Inc. / Boca Pharmacal, LLC

Specialty Generic Prescription Pharmaceuticals

Disease Overview

Specialty generics are difficult-to-formulate, niche-volume, or DEA-controlled drugs where limited competition supports premium pricing relative to commodity generics. Categories include controlled substances (Schedule II-V opioids, benzodiazepines), semisolids (creams, ointments, suppositories), and complex solutions where manufacturing scale, FDA compliance, and DEA quota access are barriers to entry.

Competitive Landscape

In 2013 the US specialty generics segment had become the most attractive corner of generics M&A as commodity generics margins compressed under Indian and Israeli competition. Major consolidators included Mallinckrodt (controlled substances and APIs spun out of Covidien July 2013), Mylan, Akorn, Lannett, and Endo's own Qualitest unit (acquired from Generics International in 2010 for $1.2B). Boca Pharmacal — Coral Springs, FL, founded 1998 — held a niche portfolio in controlled substances (generics including alprazolam/Xanax and levetiracetam/Keppra), semisolids, and solutions, projected to deliver ~$50M EBITDA on a standalone basis in 2013, implying a ~4.5x EBITDA multiple — modest by 2013 specialty generics standards. CEO Rajiv De Silva positioned the deal as the first of multiple bolt-ons under Endo's specialty healthcare transformation. The transaction closed February 2014 and was the same period Endo announced the much larger Paladin Labs acquisition that became its Irish-domiciled corporate restructuring vehicle. The FTC required limited divestitures (per the FTC consent file). (Source: https://www.ftc.gov/system/files/documents/cases/140131endobocacmpt.pdf)